Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

The deal involves an enterprise value of $85 million plus approximately $75 million in net cash held by FibroGen in China at the time of closing, totaling around $160 million. This strategic move will ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Joseph Allen discussing PSA response and survival based on metastatic site in patients with ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...